Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02420821 |
| Title | A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma |
| Acronym | IMmotion151 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Hoffmann-La Roche |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | TUR | POL | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS |